Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Metabolism, Inborn Errors 1Lymphoma, Non-Hodgkin 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Immunologic Deficiency Syndromes 1Hemoglobinopathies 1Graft vs Host Disease 1Disease Progression 1Congenital Bone Marrow Failure Syndromes 1Carcinoma in Situ 1Bone Marrow Failure Disorders 1Anemia, Refractory, with Excess of Blasts 1

Interventions

pembrolizumab 20Gemcitabine 18Cisplatin 14Magnetic Resonance Spectroscopy 13enfortumab vedotin 12Specimen Handling 10Cystectomy 10Docetaxel 8Mitomycin 7Standard of Care 6Cystoscopy 6Transurethral Resection of Bladder 5Radiotherapy 5Carboplatin 5durvalumab 4Practice Guidelines as Topic 4Nivolumab 4Radiation 3Multiparametric Magnetic Resonance Imaging 3Mitozytrex 3Fluorouracil 3tislelizumab 2dehydroftorafur 2cemiplimab 2avelumab 2alvimopan 2Therapeutics 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Urinary Bladder Neoplasms × Clinical Trials, Phase I as Topic × Clear all
NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

enGene, Inc.

Phase 1/2 Recruiting
350 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡